Funding profile · Research infrastructure

Transcriptic

About $90 million reported across nine years, under two names. Only one operating-company Form D was ever filed, and the largest announced round has no Regulation D filing on EDGAR at all.

$56.1MSeries B announced June 2021, no Form D on EDGAR
$16.5MOffered and sold in full, Strateos Form D, filed Jul 2019
$90MTotal funding reported by Forbes at the 2021 round
$2.16MRaised by two single-company SPVs, 119 investors combined

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Nov 2012 Online syndicate into the seed $147,993 39, via SecondMarket Transcriptic Fund Form D
Dec 2012 Seed $1.2M Google Ventures, FF Angel, Mark Cuban, Naval Ravikant TechCrunch
Feb 2015 Series A $8.5M Data Collective leading; IA Ventures, AME Cloud Ventures, Silicon Valley Bank, 500 Startups TechCrunch
Nov 2016 Series A extension $13.4M Data Collective leading; Digital Science, WuXi AppTec, AME Cloud Ventures VentureBeat
Apr 2019 Merger financing at the 3Scan combination $16,500,003, fully sold 4 · DCVC and Lux Capital, with Dolby Family Ventures Form D + release
Jun 2021 Series B $56.1M DCVC and Lux Capital leading; Eli Lilly participating Forbes, Fierce Biotech
Jul 2021 SPV: AVGSF – Strateos 2021, LLC $2,012,500 80 · Alumni Ventures Group Form D
Since Apr 2023 None announced None None Nothing found

What the filings show

Strateos, Inc. · Form D · filed Jul 8, 2019

First sale
Apr 29, 2019
Offered
$16,500,003 equity
Sold
$16,500,003 · $0 remaining
Investors
4 · average about $4,125,001
Exemption
Rule 506(b)
Related persons
Mark Fischer-Colbrie (executive officer, director); Chris Krueger (executive officer, signing CFO); Armen Vidian, Mara Aspinall, Jeff Finer, Joshua Wolfe (directors)
Address
3565 Haven Ave., Suite 3, Menlo Park, CA
Filing
SEC EDGAR, CIK 0001781338

AVGSF – Strateos 2021, LLC · Form D · filed Jul 14, 2021

First sale
Jul 1, 2021
Type
Venture capital fund (single-company SPV)
Sold
$2,012,500 of $2,012,500
Investors
80 · average about $25,156 · minimum accepted $25,000
Exemptions
Rule 506(b); Investment Company Act 3(c)(1)
Related persons
Michael Collins, chief executive of Alumni Ventures Group, the issuer’s sole manager
Filing
SEC EDGAR, CIK 0001872579

SecondMarket Transcriptic Fund, LLC · Form D · filed Nov 27, 2012, amended 2013 and 2019

First sale
Nov 21, 2012
Type
Pooled investment fund (single-company SPV)
Offered
Indefinite at first filing; $300,000 in the 2013 amendment
Sold
$147,993 · restated to $146,845 in 2019
Investors
39 · average about $3,795 · minimum accepted $1,000
Exemptions
Rule 506; Investment Company Act 3(c)(1)
Related persons
Bill Siegel and Jeremy Smith of SecondMarket Management, LLC; from 2019 Assure Fund Management, after the vehicle was renamed AL-Transcriptic-Fund, LLC
Filing
SEC EDGAR, CIK 0001560402

Reading the filings

  1. The biggest round left no federal trace.The $56.1 million Series B was announced June 8, 2021. No Form D for it exists under the Strateos, Inc. CIK, which has had exactly one filing since 2019. Issuers raising under Section 4(a)(2) rather than Regulation D file no Form D, so the absence is lawful, but the round is documented only by press coverage. Its one federal artifact is a side vehicle: Alumni Ventures put in $2,012,500 from 80 investors on July 1, 2021.
  2. The merger money landed before the merger was announced.First sale on the $16,500,003 was April 29, 2019; the Transcriptic and 3Scan combination was announced June 3, 2019. The Form D was filed July 8, seventy days after first sale, well past the fifteen-day deadline in Rule 503. Four investors averaged about $4.1 million each, matching a release naming DCVC, Lux Capital and Dolby Family Ventures.
  3. The announcement and the 2012 filing do not agree.Transcriptic told TechCrunch that more than 60 accredited investors contributed $150,000 through AngelList and SecondMarket, and called it the first significant equity round raised online. The Form D filed six days earlier reports 39 investors and $147,993 sold. A 2013 amendment raised the offering to $300,000 but the amount sold never moved.
  4. Small checks came through vehicles, never the cap table.The 2012 syndicate averaged about $3,795 a person, the 2021 Alumni Ventures vehicle about $25,156. Both were 3(c)(1) pooled funds, so 119 investors appear on EDGAR as two lines.
  5. An orphaned SPV outlived its sponsor.In April 2019 the 2012 vehicle reappeared as AL-Transcriptic-Fund, LLC under Assure Fund Management, amount sold restated to $146,845, in the same month the merger financing had its first sale.
  6. The board changed without a filing to show it.The 2019 Form D lists six related persons. By March 2022 DCVC partner Jason Pontin was chairman and Jeff Finer, chair for the prior three years, had moved to independent director. No later filing records the board.

Commercial signals

Signal Detail Source type
Anchor partner Eli Lilly built the 11,500 square foot Life Sciences Studio in San Diego; Strateos operated it from January 2020. Lilly sold it to Arctoris in September 2024. Independent
Licensed software Ginkgo Bioworks holds a perpetual, royalty-free license to the software. The collaboration agreement behind it, signed October 2017, expired in 2022. Public record
Revenue Never disclosed. Forbes reported the chief executive putting it in the tens of millions in 2021 while declining to be exact. Company-stated
Customers Some 100 customers reported in 2021, including Amgen, AbbVie, Ginkgo Bioworks and DARPA. No contract values published. Company-stated
Business model change April 2023: from operating its own cloud labs to deploying LodeStar software on customer sites, with a staffing reorganization. Company-stated
Operating status No announcement since April 18, 2023. The web sites still load but carry unrelated inserted promotional text and zeroed metric counters. No record of a sale, dissolution or bankruptcy was found. Not found

What to watch

  • Any new filing under CIK 0001781338. There has been none since July 2019.
  • A Delaware or California entity status change for Strateos, Inc.
  • Any assignment of the LodeStar software or the Menlo Park assets.

The Transcriptic story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Synapticure: Shared investor: Assure Fund Management. A virtual specialty clinic for ALS, Parkinson’s and dementia, built by an ALS patient and his caregiver
  • Culture Biosciences: Shared investor: Data Collective. A cloud lab that ran other companies’ fermentation for them, now selling the bioreactor itself through Cytiva
  • Enzyme: Shared investor: Data Collective. Cloud quality management software built so small life science companies could survive an FDA inspection without hiring a consulting firm
  • Numerion Labs: Shared investor: Ame Cloud Ventures. Formerly Atomwise

Sources

  1. Public recordForm D, Strateos, Inc.SEC · Jul 8, 2019
  2. Public recordForm D, AVGSF – Strateos 2021, LLCSEC · Jul 14, 2021
  3. Public recordForm D and amendments, SecondMarket Transcriptic Fund and AL-Transcriptic-FundSEC · 2012 to 2019
  4. Public recordGinkgo Bioworks Holdings, Inc. annual report on Form 10-KSEC · Feb 29, 2024
  5. Public recordBionano Genomics, Inc. proxy statement, Yvonne Linney biographySEC · Apr 2, 2026
  6. IndependentRemote-Controlled Labs? Strateos Raises $56 MillionForbes, Amy Feldman · Jun 8, 2021
  7. IndependentStrateos scores $56M for its SmartLab platformFierce Biotech · Jun 8, 2021
  8. IndependentTranscriptic seed, Series A and 2016 extension coverageTechCrunch and VentureBeat · 2012 to 2016
  9. IndependentEli Lilly sells Life Sciences Studio lab to ArctorisFierce Biotech · Sep 13, 2024
  10. CompanyStrateos combines Transcriptic and 3ScanGlobeNewswire · Jun 3, 2019
  11. CompanyStrateos Expands Leadership TeamBusiness Wire · Mar 2022
  12. CompanyStrateos Announces Strategic Shift to On-Site Cloud LabsBusiness Wire · Apr 18, 2023

Compiled from SEC and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Transcriptic or Strateos. This page is not an offer to sell or a recommendation to buy any security.